Law360, New York (March 17, 2017, 7:42 PM EDT) -- Bowing to pressure from Big Pharma, the U.S. Food and Drug Administration on Friday delayed by one year a controversial new rule that endorsed a broad approach to determining whether drug and device makers are engaged in off-label promotion.
The delay to March 19, 2018 came in response to a citizen petition filed last month by Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization and a drugmaker coalition called the Medical Information Working Group. The petition, which sought a stay and reconsideration, strongly criticized a final rule related to “intended use” — a concept that looks at whether manufacturers...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!